Skip to main content
Terug
CLDX logo

Celldex Therapeutics, Inc.

Datakwaliteit: 100%
CLDX
NASDAQ Healthcare Biotechnology
€ 31,80
▲ € 0,90 (2,91%)
Marktkapitalisatie: 2,12B
Dagbereik
€ 31,76 € 34,51
52-Weeksbereik
€ 14,40 € 34,51
Volume
1.447.271
50D / 200D Gem.
€ 26,77 / € 24,92
Vorige Slotkoers
€ 30,90

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -8,2 0,4
P/B 4,0 2,9
ROE % -40,6 3,7
Net Margin % -17253,3 3,8
Rev Growth 5Y % -24,6 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue declined -24,64% annually over 5 years
Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -213,66M
Revenue growth is decelerating — 1Y growth trails 5Y average by 53,99%
Capital intensive — 180,93% of revenue goes to capex

Groei

Revenue Growth (5Y)
-24,64%
Revenue (1Y)-78,63%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-40,62%
ROIC-40,71%
Net Margin-17253,33%
Op. Margin-19160,00%

Veiligheid

Debt / Equity
0,00
Current Ratio10,49
Interest Coverage0,00

Waardering

P/E Ratio
-8,18
P/B Ratio4,02
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -78,63% Revenue Growth (3Y) -53,32%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -24,64% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,50M Net Income (TTM) -258,80M
ROE -40,62% ROA -44,39%
Gross Margin 100,00% Operating Margin -19160,00%
Net Margin -17253,33% Free Cash Flow (TTM) -213,66M
ROIC -40,71% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 10,49
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -8,18 P/B Ratio 4,02
P/S Ratio 1411,21 PEG Ratio -0,12
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,12B Enterprise Value 2,09B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,50M 7,02M 6,88M 2,36M 4,65M
Net Income -258,80M -157,86M -141,43M -112,33M -70,51M
EPS (Diluted) -3,90 -2,45 -2,92 -2,40 -1,64
Gross Profit 1,50M -156,53M -111,13M -79,90M -48,66M
Operating Income -287,40M -195,08M -154,54M -115,23M -71,24M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 582,98M 792,34M 465,63M 352,74M 444,65M
Total Liabilities 55,82M 45,34M 36,46M 26,53M 25,18M
Shareholders' Equity 527,17M 747,01M 429,17M 326,20M 419,48M
Total Debt 2,34M 3,81M 2,54M 4,03M 3,04M
Cash & Equivalents 28,87M 28,36M 34,81M 29,43M 39,14M
Current Assets 534,66M 747,16M 431,69M 317,69M 410,84M
Current Liabilities 50,99M 39,50M 31,13M 18,61M 16,53M